United Therapeutics reported that its Phase 1 study of the miroliverELAP external liver assist device achieved a 100 % survival rate among five patients with acute liver failure, acute‑on‑chronic liver failure, or severe acute alcoholic hepatitis, all of whom completed a 32‑day follow‑up without any unexpected serious adverse events. The study, the world’s first FDA‑cleared clinical trial of a bioengineered liver, was conducted by Miromatrix Medical, a wholly owned subsidiary, and was completed in late 2025 with data analysis finalized in early 2026.
The results address a critical unmet need. Acute liver failure carries a mortality rate of roughly 30 % for patients who cannot receive a transplant, largely because donor organs are scarce. By providing temporary hepatic support, miroliverELAP offers a bridge that can give the native liver time to recover, potentially reducing the need for transplantation and improving survival in this high‑risk population.
miroliverELAP is built on a decellularized porcine liver scaffold that is seeded with human hepatocytes and endothelial cells. The device functions as an external assist, filtering blood and performing key liver functions while the patient’s own liver heals. This technology exemplifies Miromatrix’s broader strategy of creating bioengineered organ alternatives for heart, kidney, and lung as well.
United Therapeutics’ leadership highlighted the milestone as a key step in expanding its organ manufacturing portfolio. The company’s strong balance sheet—cash and equivalents exceeding debt, a market capitalization of about $20 billion, and a gross margin of 88 %—provides the financial foundation to pursue further development. A Phase 2 study is planned, with enrollment and data collection expected to begin in the first half of 2027, and full results are anticipated in the second half of 2026.
"This study demonstrates the safety and feasibility of miroliverELAP in patients who have no other options," said Dr. Martine Rothblatt, Chair and CEO. “It confirms our commitment to expanding the availability of transplantable organs and brings us closer to a future where organ shortages no longer dictate patient outcomes.” Jeff Ross, Ph.D., President of Miromatrix, added, “The positive safety profile and survival outcomes give us confidence to advance miroliverELAP toward broader clinical use and regulatory approval.”
The company’s next steps include scaling up manufacturing, refining the device’s integration with clinical workflows, and initiating the Phase 2 trial. Successful completion of the next study phase would support regulatory submissions and could open a new therapeutic pathway for patients with acute liver failure who are currently beyond the reach of transplantation.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.